If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
137
results.
Updated on
07/05/2026 [09:27:00]
Absstract of: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Absstract of: AU2024354463A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Absstract of: US20260114804A1
0000 Disclosed herein, in some aspects, are systems and methods for determining and/or monitoring a stool condition for a subject. In some embodiments, the stool condition is based on one or more images of stool of a subject. In some embodiments, the stool condition correlates with a stool assessment comprising i) a characterization of the stool according to a plurality of characteristics, and/or ii) identifying one or more medical conditions, illnesses, and/or diseases associated with the stool. In some embodiments, the stool condition is determined using one or more Artificial Intelligence engines using a trained data set. In some embodiments, the stool condition is based on one or more stool assessments performed for one or more stools corresponding to one or more bowel movements over a period of time.
Absstract of: AU2024362918A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Absstract of: US20260109755A1
0000 The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
Absstract of: WO2026080407A1
Provided herein are methods and systems for detection of precancer or cancer. The method may comprise using cell-free nucleic acids. The methods may comprise assaying nucleic acids. The method may comprise extracting cell-free nucleic acids. The methods may comprise generating libraries based at least on cell-free nucleic acids.
Absstract of: KR20260045660A
본 발명은 크론병 환자 십이지장 오가노이드 유래 장 상피 단층 모델의 분화 방법에 관한 것으로, 발명의 장 상피 단층 모델은 3차원 십이지장 오가노이드로부터 해리된 단일 세포에 기초하여 분화를 유도한 것으로, 다양한 장 상피 세포 유형을 포함하고 내강(lumen)에 대한 접근성을 제공한다. 또한, 본 모델은 실제 환자 장 점막의 구조와 기능을 효과적으로 모사할 수 있어 염증성 장질환을 포함한 다양한 장 질환의 병태생리 연구뿐만 아니라, 후보 물질의 효능 및 안전성을 평가하는 데 유용하게 활용될 수 있다.
Absstract of: WO2026064841A1
The present invention relates in part to methods of detecting Mycobacterium avium subsp. paratuberculosis in ruminant animals and markers for use in such methods.
Absstract of: AU2026201512A1
The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS). eb e b
Absstract of: WO2026072849A2
The present disclosure provides pharmaceutical compositions, dosage forms comprising the pharmaceutical composition, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, and treating colorectal cancer in a subject in need thereof, comprising administering the pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.
Absstract of: US20260083739A1
Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.
Absstract of: US20260085112A1
The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.
Absstract of: WO2024236584A1
Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.
Absstract of: WO2024227011A1
Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Absstract of: US20260060660A1
The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.
Absstract of: WO2026047225A1
Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.
Absstract of: AU2026201149A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn’s disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and 5 kits for predicting the response to the therapy of the inflammatory bowel disease. eb e b
Absstract of: DE102024124516A1
Ein Prüfkörper (10), ibs. zum Eindrücken in einen zu prüfenden Gegenstand (12), der bsw. ein Umhüllungssystem für erdverlegte Stahlrohre (14) ist, hat die Gestalt eines Pyramidenstumpfes, Kegelstumpfes oder einer Halbkugelschicht mit einer Grundfläche (10g) und einer Deckfläche (10d), wobei- die Projektion der Deckfläche auf die Grundfläche innerhalb der Grundfläche liegt;- die Deckfläche parallel zu der Grundfläche ist.Ein Verfahren zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst, dass- der Prüfkörper mit der Deckfläche voran von außen gegen das Umhüllungssystem gemäß einem vorbestimmten Wegverlauf und/oder Kraftverlauf gedrückt wird;- die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfasst wird;- die Belastbarkeit abhängig von der erfassten Eindringtiefe ermittelt wird.Ein Prüfstand (16) zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst- ein Haltesystem (18);- eine Materialprüfmaschine (20), die den Prüfkörper mit der Deckfläche voran gegen das Umhüllungssystem drücken kann;- eine Messeinrichtung (22), die die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfassen kann;- eine Steuereinrichtung (24), die gemäß dem Verfahren die Materialprüfmaschine und die Messeinrichtung ansteuern und die Belastbarkeit ermitteln kann.Der Prüfkörper wird zum Ermitteln der mechanischen Belastbarkeit gemäß dem Verfahre
Absstract of: WO2026050646A1
This disclosure concerns metabolites that can be used to identify and characterize inflammatory bowel disease (IBD) as well as assess treatment for IBD.
Absstract of: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Absstract of: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Absstract of: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Absstract of: CN121575078A
本发明涉及生物医学工程，公开了一种基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用。该筛选方法包括以下步骤：采用表面经仿生化处理的超表面等离子共振生物芯片，进行肠壁细胞培养或者小胶质细胞培养获得肠壁细胞贴壁或者小胶质细胞贴壁的芯片板，在细胞贴壁的芯片板内加入含化疗药物或脂多糖的培养基进行培养I，再除去培养基、加入待测治疗剂进行培养II得到培养液，检测所述培养液中肠壁细胞或者小胶质细胞的细胞修复效果；筛选获得对肠壁细胞和/或小胶质细胞具有修复作用的治疗剂。该筛选方法能够从多个待测治疗剂中高效、准确地筛选出兼具肠道调节与神经保护双重功效的治疗剂，且能够实现无标记、实时在线动态监测与探究治疗剂和细胞的相互作用情况。
Absstract of: CN121570596A
The invention relates to the technical field of biological medicines, in particular to application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases. The invention provides an application of a substance for inhibiting the activity of RNF219 protein or a substance for reducing the content of RNF219 protein in preparation of drugs for preventing or treating inflammatory diseases, especially drugs for preventing or treating sepsis and colitis. According to the application, a mouse acute infection model is constructed to prove that RNF219 defect inhibits the inflammatory reaction degree and inflammatory injury induced by LPS (Lipopolysaccharide); in a mouse with DSS-induced colitis, the RNF219 defect can delay the disease progress of the mouse colitis and improve the inflammatory phenotype of the mouse. Therefore, the function of the RNF219 in natural immune response is defined, and the RNF219 has important scientific significance on prevention and treatment of immune inflammation related diseases such as sepsis and inflammatory bowel diseases.
Absstract of: US20260053426A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Absstract of: US20260055183A1
Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.
Absstract of: US20260057960A1
Disclosed herein are methods and systems for administering therapy to subjects who have been determined to display or not display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the therapy. The subject and prior subjects may suffer from a disease, disorder, or condition for which it is desired to predict whether the subject will respond to the therapy. In an aspect, the disease, disorder, or condition may be an autoimmune disorder such as ulcerative colitis. The subject may be administered an anti-TNF therapy or an alternative to anti-TNF therapy based upon predictions provided by methods and systems described herein.
Absstract of: CN121559077A
本发明公开了基于荧光探针的ATP水解酶抗体高效筛选法，包括生化体系和细胞体系两种检测方案，在生化体系中，通过定量ENTPD2蛋白水解ATP后剩余量，直接计算抗体抑制率；在细胞体系中，利用过表达ENTPD2的细胞验证抗体对跨膜酶的抑制功能。该生化体系方法无需抗体纯化，仅需5-15μL B细胞上清液即可完成初筛，筛选准确度高(细胞体系可用作验证筛选得到的抗体)，与体内药效结果一致，适用于抗ENTPD2抗体药物的开发，显著降低研发成本。
Absstract of: CN121565478A
The invention relates to a Crohn disease auxiliary prediction method based on machine learning. The method comprises the following steps: obtaining related prediction data of a user; whether missing items exist in the user related prediction data is judged, if yes, an alarm is given to remind a user to supplement, if the user confirms that supplement cannot be carried out, self-adaptive complementation is carried out, and finally to-be-predicted data is formed; inputting the to-be-predicted data into a pre-established Crohn disease auxiliary prediction model, and outputting a prediction result by the Crohn disease auxiliary prediction model; the Crohn disease auxiliary prediction model is constructed based on an XGBoost model; and visually displaying the prediction result to inform a user. According to the method, when the data input by the user is missing, the user can be reminded to supplement, if the data cannot be supplemented, self-adaptive complementation is carried out, the prediction accuracy of the model is improved, Crohn disease risk prediction can be carried out according to the existing indexes of the patient, the user can conveniently find related risks in time, and the user experience is improved. And the diagnosis and treatment efficiency of the user is improved.
Absstract of: US2024254217A1
The present disclosure generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.
Absstract of: CN121532526A
The present disclosure provides methods and compositions for determining the risk of a patient unresponsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody, and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Absstract of: ES3055703A1
Biomarkers of inflammatory bowel diseases. The present invention relates to a method for early determination of whether a subject has an inflammatory bowel disease, comprising determining the expression product level of at least one biomarker, from a biological sample of a subject, selected from: ATRN, PRDX4, MOAB and AZU1. (Machine-translation by Google Translate, not legally binding)
Absstract of: CN121512985A
The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.
Absstract of: WO2026034527A1
Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and/or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.
Absstract of: WO2024206308A2
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Absstract of: CN121499685A
The invention discloses a multi-index content determination method of hovenia acerba and rhizoma atractylodis bowel-relaxing granules, and belongs to the technical field of traditional Chinese medicine detection. The invention establishes a high performance liquid chromatography method for simultaneously determining nine components including caffeic acid, chicoric acid, naringin, naringin, hesperidin, neohesperidin, chrysophanol, aurantio-obtusin and atractylenolide I in a preparation, and the content of the components is calculated through a relative correction factor by taking caffeic acid as an internal reference by adopting a quantitative analysis of multi-components by single marker. According to the method, effective detection of the immature bitter orange medicinal material and the immature bitter orange base source is realized, and the immature bitter orange and the sweet orange base source of the traditional Chinese medicine immature bitter orange can be accurately distinguished, so that more comprehensive and accurate quality control of the traditional Chinese medicine is realized, and the stability and consistency of clinical efficacy of the traditional Chinese medicine are guaranteed.
Absstract of: EP4417707A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Absstract of: CN121472476A
The invention discloses a citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis. According to the invention, a genome typing technology in a whole genome range is adopted, and a set of discrimination system capable of accurately identifying real hybrid offspring is established through high-density SNP (Single Nucleotide Polymorphism) marker analysis and an IBD (Identity by means of an algorithm. The method breaks through the limitation of a traditional method on hybrid filial generation identification, and provides reliable technical support for breeding practice.
Absstract of: WO2026027669A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Absstract of: WO2026027676A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Absstract of: US20260036584A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Absstract of: CN121445742A
本发明涉及双氢麦角胺在制备预防和/或治疗炎症性肠病的药物中的应用。本发明在炎症性肠病模型中验证得出一种全新的作用机制：炎症条件下TRIM25会介导LSD1的泛素化降解，引起肠上皮组织代谢紊乱加剧炎症。本发明通过预测TRIM25和LSD1结合的结构信息，使用虚拟药物筛选，筛到了双氢麦角胺小分子化合物，其可很好地占据TRIM25和LSD1互作的结合位点，抑制TRIM25和LSD1的互作，从而抑制LSD1的降解；在DSS诱导的小鼠结肠炎模型中，双氢麦角胺能缓解肠上皮因代谢紊乱造成的炎症激活，很好地缓解炎症性肠病的症状。上述过程作用机制明确，效果显著，实现了双氢麦角胺在治疗炎症性肠病方面的老药新用，具有较高的临床应用价值。
Absstract of: CN121454070A
本发明公开了琥珀酸对坏死性小肠结肠炎影响机制的研究方法，涉及生物医学研究技术领域；包括如下步骤：S1：动物模型建立：选择新生小鼠，随机分为4组；S2：干预周期：持续处理3‑5天，每日记录体重、存活率及存活状态；S3：样本采集：处死小鼠，取肠组织，分装用于不同检测；S4：多维度检测；S5：数据分析：整合表型、病理、分子数据，验证琥珀酸‑SUCNR1轴的功能。本发明构建了完整的研究琥珀酸‑SUCNR1轴在坏死性小肠结肠炎中作用机制的技术体系，通过动物模型构建、分子机制验证和病理评估的有机结合，形成了从现象观察到机制阐明的完整证据链，确保研究结论的可靠性。
Absstract of: CN121426979A
The invention belongs to the technical field of biological medicine, and particularly discloses cistanche polysaccharide as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, washing, drying and crushing fresh cistanche, and removing impurities with absolute ethyl alcohol to obtain a reactant; s2, putting the reactant obtained in the step S1 into hot water for extraction, and adding absolute ethyl alcohol for precipitation after concentration to obtain crude polysaccharide; s3, adding a chloroform-n-butyl alcohol solution for deproteinization, and removing pigments by using macroporous resin; s4, chromatographic purification is conducted through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence, polysaccharide components are collected, dialysis and freeze-drying are conducted, and the cistanche deserticola polysaccharide is obtained. The cistanche deserticola polysaccharide has a remarkable anti-inflammatory effect, can improve the richness and uniformity of intestinal flora, optimize flora balance and maintain the barrier function of the intestinal tract, and has a wide prospect in preparation of medicines for preventing or treating colitis.
Absstract of: WO2026024847A2
Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.
Absstract of: EP4684799A2
Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Absstract of: CN121410275A
The invention relates to a joint detection kit for predicting endoscopic response of inflammatory bowel disease in the technical field of medical examination, and solves the technical problem that the existing single biomarker is limited in detection sensitivity and specificity. Comprising an excrement calprotectin detection reagent and an excrement lactoferrin detection reagent, a monoclonal antibody sandwich ELISA method is adopted for calprotectin detection, and the detection range is 10-3000 mu g/g; the lactoferrin is detected by adopting a chemiluminescence immunoassay method, and the detection range is 5-500mu g/g. An endoscopic response prediction scoring model is established based on calprotectin concentration X and lactoferrin concentration Y: prediction score = alpha * ln (X + 1) + beta * ln (Y + 1) + clinical correction factor, alpha is 0.65-0.75, beta is 0.45-0.55, and the clinical correction factor integrates C-reactive protein, fecal occult blood and patient age. Compared with single detection, the sensitivity is improved to 85%-88%, and the specificity is improved to 83%-86%.
Absstract of: CN121385324A
The invention belongs to the field of biological medicine, and particularly relates to application of soluble B7-H5 in preparation of a Crohn disease detection reagent. According to the invention, the level of soluble B7-H5 (sB7-H5) in serum of a patient suffering from Crohn's disease (CD) is deeply analyzed by using an ELISA (Enzyme-Linked Immunosorbent Assay) technology. Studies find that sB7-H5 in serum of a CD patient is remarkably and highly expressed and is positively correlated with a disease activity index (CDAI). Further experimental verification shows that blocking of B7-H5 can promote polarization of inflammatory macrophages. Based on the discoveries, the invention provides the application of the serum B7-H5 as the molecular marker of the Crohn's disease to development of products for detection, prognosis or treatment of the Crohn's disease. The molecular marker can be in a soluble B7-H5 gene or protein form. The invention also shows that the B7-H5 can be used as a potential target for developing the medicine for preventing and treating the Crohn disease, and has important clinical application value.
Absstract of: CN119433017A
The invention discloses an application of CCDC71L in diagnosis and treatment of radiation enteritis, and provides an application of a reagent for detecting the expression level of the CCDC71L in preparation of a product for diagnosing radiation enteritis and an application of an inhibitor of the CCDC71L in preparation of a medicine for treating radiation enteritis. The invention further provides a method for screening candidate drugs for treating or preventing radiation enteritis and a method for inhibiting the expression level of inflammatory factors in macrophages. Experiments prove that the CCDC71L can realize diagnosis of radiation enteritis, and discovers that inhibition of the CCDC71L can inhibit infiltration and polarization of macrophages so as to inhibit radiation-induced inflammatory reaction, and the CCDC71L marker provided by the invention provides a new idea for diagnosis and treatment of radiation enteritis, and has a wide application prospect.
Absstract of: WO2026020057A1
This disclosure provides for method for the diagnosis, prognosis and treatment of inflammatory bowel disease (IBD) and clinical subtypes of IBD in a subject by detecting the presence or level of one or more immune responses to self and microbial antigens in a sample from a subject.
Absstract of: US20260022426A1
Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool/fecal samples from premature newborns/babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.
Absstract of: CN121354908A
The invention discloses a Crohn disease postoperative bad outcome prediction method combining knowledge base construction and an experience-driven self-asking mechanism, and solves the problems of insufficient interpretability, insufficient clinical data utilization, weak generalization ability and the like of an existing prediction method. The method comprises the following steps: constructing a Crohn disease special medical knowledge base, extracting disease progress related factors from medical literatures and real medical records, and carrying out expert score weighting processing to form searchable knowledge entries; retrieving related knowledge injection context from a knowledge base based on a medical record input by a user, and generating preliminary prediction by using a large language model; structured reasoning is guided through a multi-layer prompt engine, diagnosis tasks are decomposed through the thinking chain technology, and self-check before reasoning is achieved by driving a self-asking mechanism through experience. And generating an introspection problem chain according to historical error cases, iteratively optimizing the reasoning process, and finally outputting a bad outcome prediction result and a detailed analysis report. According to the method, both traceable interpretability and prediction accuracy are considered, and reliable assistance is provided for postoperative clinical management of Crohn's disease.
Absstract of: CN121353785A
The invention discloses an inflammatory bowel disease classification and interpretable diagnosis method and system based on deep learning, an image acquisition module acquires image frames from colonoscope videos, and an image preprocessing module rejects low-quality images with high black pixel proportion and blurred images and executes color space normalization. The qualified image is sent to a double-stage segmentation model to obtain a polyp area mask image, the mask image is used for positioning an ROI image of the polyp area, the ROI image is input into a polyp classification model constructed based on a visual Transform structure, and a hyperplasia type or adenoma type classification result is obtained. According to the method, on the premise that extra cost input is not needed, the efficiency and accuracy of polyp recognition and grading in the colonoscope image are greatly improved, manual subjective errors are reduced, and the intelligent level and clinical practicability of early intestinal cancer screening are improved.
Absstract of: CN121344176A
The invention discloses an application of miR-32-5p in diagnosis and treatment of fungal ulcerative colitis. The invention finds that the expression of the miR-32-5p in an ulcerative colitis model under C.aldicans pre-planting is reduced, and the colon length of a mouse and the expression of intestinal barrier related protein in an NCM460 cell can be recovered by further increasing the expression of the miR-32-5p. Based on the discovery, the miR-32-5p can be used as a miRNA marker closely related to the fungal ulcerative colitis, is applied to preparation of diagnostic products and prevention and treatment drugs for the fungal ulcerative colitis, and provides a new thought and tool for noninvasive early diagnosis and later treatment of the ulcerative colitis.
Absstract of: CN121344178A
The invention provides an irritable bowel syndrome risk marker based on genomics. The risk marker comprises the following six pathogenic genes: CADM2, PHF2, PCLO, SHISA6, LRP1B and TANK. According to the invention, not only is the effect of the latest large-scale whole genome association research (GWAS) on the aspect of analyzing the genetic cause of the irritable bowel syndrome shown, but also five new genetic risk variation, potential unreported pathogenic genes and treatment targets of the irritable bowel syndrome are found; a new insight is provided for the cause of the irritable bowel syndrome, and a potential therapeutic intervention target is highlighted. The invention also provides an application based on the risk marker of the irritable bowel syndrome and a corresponding early screening kit.
Absstract of: AU2024307935A1
Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.
Absstract of: US20260016486A1
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.
Absstract of: AU2024283890A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Absstract of: CN121324673A
The invention discloses an electrochemical sensor for IBD protein marker detection as well as a preparation method and application of the electrochemical sensor. The electrochemical sensor is composed of a semi-cured PDMS flexible substrate in which CNT is embedded, deposited gold nanoparticles and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta1 sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta1 sensor all adopt aptamer single chains modified by signal molecule methylene blue, and correspondingly adopt nucleotide sequences shown in SEQ ID NO.1-4. Matching and excellent biocompatibility of the sensor and human tissue modulus can be improved, and accurate detection of low-concentration biomarkers and stable signal output of the sensor under the strain working condition are achieved.
Absstract of: CN121294684A
The invention relates to a microbial composition for screening an intestinal bacteria transplantation material for treating ulcerative colitis (UC) as well as a screening method and application of the microbial composition, and belongs to the technical field of screening of intestinal bacteria transplantation materials. The invention provides a microbial composition for screening an intestinal bacteria transplantation material for treating UC. The microbial composition is prepared from the following microorganisms: Escherichia coli, anaerobe przewalskii, bacteroides shavieri, ruminococcus bromide, parabacteroides faecalis and visceral odorobacter. According to the six characteristic bacteria and the relative abundance of the six characteristic bacteria constructed by the invention, an intestinal bacteria transplantation material with relatively high content of the six bacteria can be screened out, the remission rate of UC treatment can be improved to 89.5%, and intestinal barrier healing of a patient is enhanced. When the kit is used for detecting six characteristic bacteria in the intestinal bacteria transplantation material, the specificity is high, and the sensitivity is strong; and the detection process is simple, non-invasive and low in cost.
Absstract of: US20260008842A1
The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
Absstract of: CN121272040A
The invention discloses an application of SETD2 and NSD2 in diagnosis and treatment of aging of intestinal stem cells. Specifically, the invention relates to application of the intestinal stem cell aging marker or the detection reagent thereof, the intestinal stem cell aging marker or the detection reagent thereof is used for preparing a diagnostic reagent or a diagnostic kit, and the diagnostic reagent or the diagnostic kit is used for judging whether intestinal stem cells are aged or not. Wherein the senescence marker combination is prepared from SETD2 and NSD2 (National Solution Development 2). Meanwhile, the invention provides a detection reagent and a kit for the intestinal stem cell marker. The detection reagent or the kit can effectively judge the aging type of the intestinal stem cells, and different effective drugs are effectively used according to different types.
Absstract of: CN121280339A
The invention discloses a Crohn disease focus automatic segmentation and activity evaluation system based on deep learning, which belongs to the field of medical artificial intelligence and comprises a data preprocessing unit, a focus automatic segmentation unit, a radiomics feature extraction unit, a feature screening and dimension reduction unit and an activity classification unit. According to the method, an nnU-Net deep learning segmentation model is combined with image omics feature extraction, multi-stage feature screening and machine learning classification technologies, so that full-process automation from CTE image preprocessing, focus automatic segmentation, feature extraction and screening to activity classification is realized. The system can efficiently and accurately segment the focus of Crohn's disease, automatically assesses the disease activity based on the screened key radiomics characteristics, significantly improves the consistency, objectivity and efficiency of diagnosis, and is suitable for clinical auxiliary diagnosis and scientific research analysis.
Absstract of: CN121276058A
The invention provides a Crohn disease early screening marker based on plasma proteomics. The early screening marker comprises the following nine proteins: CD274, CHI 3L1, REG1B, ITGAV, PRSS8, ITGA11, GDF15, DEFA1DEFA1B and IL6. The early screening marker provided by the invention can accurately and non-invasively predict CD as long as 16 years before diagnosis, which provides an important value for early screening of CD high risk groups and formulation of intervention measures. The invention also provides application of the Crohn disease early screening marker and an early screening kit for Crohn disease prediction.
Absstract of: WO2026006246A1
The disclosure provides an evaluation of the virome in health and disease of the oral-gut-brain axis, in particular, periodontitis, irritable bowel disease (IBD) and Alzheimer's Disease (AD). For Alzheimer's disease, a striking feature was found via metagenomics of brain autopsy specimens - the presence of parvoviridae (comprised of erythoviruses and erythroparvoviruses) in the brains of individuals diagnosed with Alzheimer's Disease (AD) but not in brains from age-matched healthy individuals without a medical diagnosis of AD. For IBD, For Periodontitis and IBD, an analysis revealed the top 20 most abundant viral and bacterial species in saliva samples from individuals with periodontal disease or with a healthy periodontium and the top viral and bacterial species in stool samples from individuals with irritable bowel syndrome or with gastrointestinal health. Building upon these discoveries, a number of diagnostic methods and materials for AD and IBD are described herein.
Absstract of: CN121249871A
The invention belongs to the technical field of molecular biology, and discloses application of DDX24 in maintaining the homeostasis of an intestinal vascular barrier. According to the present invention, the low expression of the intestinal microvascular endothelial DDX24 in the inflammatory bowel disease (IBD) is firstly found so as to construct the adult endothelial cell specific DDX24 induced knockout mouse model, the homeostasis of the intestinal vascular barrier (GVB) of the mouse is imbalanced, and the mouse suffers from spontaneous enteritis, such that the intestinal microvascular endothelial cell DDX24 is the important molecule for maintaining the intestinal homeostasis; and mechanism research finds that the intestinal microvascular endothelial cell DDX24 inhibits cell senescence to protect the GVB steady state. The research discloses an important mechanism of DDX24 for protecting GVB homeostasis by inhibiting intestinal microvascular endothelial cell senescence for the first time, and provides a strategy and basis for clinical diagnosis and treatment of IBD vascular barrier.
Absstract of: CN121242609A
The invention discloses a mucous membrane healing evaluation method based on energy spectrum CT iodine quantification, and belongs to the field of medical image processing and clinical diagnose.The mucous membrane healing evaluation method comprises the following steps that an energy spectrum CT intestinal stage scanning image of a patient suffering from Crohn's disease is obtained, and a three-dimensional volume area of a diseased intestinal segment is delineated on an energy spectrum CT iodine substance decomposition graph; selecting a reference blood vessel area, and measuring an iodine concentration value; calculating a normalized iodine concentration value, wherein the normalized iodine concentration value is equal to a result obtained by dividing the iodine concentration value of the lesion intestinal segment by the iodine concentration value of the reference blood vessel region; and comparing the normalized iodine concentration value with a preset threshold value 0.44, if the normalized iodine concentration value is less than 0.44, determining that the mucous membrane is healed, otherwise, determining that the active inflammation is caused. According to the scheme, traditional invasive enteroscopy is replaced with energy spectrum CT image analysis, contraindications of endoscope operation, patient pain and examination blind areas are avoided, the acceptability and examination feasibility of patients are remarkably improved, and the method is particularly suitable for p
Absstract of: US20260000713A1
Provided herein are methods of predicting a likelihood that a subject will develop ileitis, intestinal fibrosis or colitis based on an amount of acetate or acetate-producing bacteria detected in a sample obtained from a subject. Certain genetic risk variants at TNF super-family member 15 (TNFSF15) may also be detected. Methods, systems and kits for treatment of develop ileitis, intestinal fibrosis or colitis are also provided, which include inhibitors of acetate or acetate-producing bacteria, or targeting biologic therapeutics, such as inhibitors of Tumor necrosis factor (TNF)-like cytokine 1A (TL1A).
Absstract of: WO2024176230A1
The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.
Absstract of: WO2025264878A1
Provided herein are methods for treating an autoimmune disease or a fibrotic disease in a subject comprising administering to the subject an effective amount of an agent to modulate the activity of a population of T-cells expressing one or more of the targets identified herein, thereby treating the autoimmune disease or fibrotic disease in the subject.
Absstract of: CN121196614A
The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.
Absstract of: US2025389717A1
The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.
Absstract of: EP4667476A1
0001 The present disclosure relates to a technique for synthesizing with high yield a novel compound targeting mitochondria through a simple process, and the novel compound synthesized thereby. The novel compound targeting mitochondria of the present disclosure can be synthesized with high yield through a simple process and the compound thus prepared and nanoparticles containing same exhibit the therapeutic effects of targeting mitochondria, inhibiting gastric cancer, and treating inflammatory bowel disease, and systemic sclerosis and thus can be utilized for mitochondrial targeting applications, as anticancer compositions, or as therapeutic compositions for immune diseases.
Absstract of: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: WO2025259880A1
Provided herein are materials and methods for determining responsiveness of any therapy that enhances regulatory T cell (Treg) function in the treatment of inflammatory bowel disease (IBD). The materials and methods provided herein may be used to determine low dose IL- 2 responsiveness in a subject having an inflammatory bowel disease. The materials and methods can be used to determine low dose IL- 2 responsiveness in a blood sample prior to administering a low dose IL-2 therapy.
Absstract of: WO2025257752A1
This invention relates to methods of detecting inflammatory disease in a subject by detecting circulating microclots, based on combined detection or co-detection of fibrin amyloid microclots and components from Neutrophil Extracellular Traps in a sample from the subject, wherein an increased presence of fibrin amyloid microclots and NETs in the sample compared to a control or reference value is indicative of inflammatory disease in the subject. The invention also relates to kits for detecting circulating microclots to be used in the methods of detecting inflammatory disease.
Absstract of: EP4663746A2
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
Absstract of: CN121148713A
The invention discloses a differential diagnosis model (BC-ACTUAL) for Crohn's disease and gastrointestinal behcet disease and application of the differential diagnosis model. Specifically, the invention discloses application of an index combination (Age, C4, TP, UA, ALP and LDH) or a reagent for detecting the index combination in preparation of a product for differential diagnosis of Crohn's disease and gastrointestinal behcet disease. The invention also discloses a logistic regression model established by using the index combination and a scoring system. The model has the characteristics of high sensitivity, good specificity, economy, high efficiency and convenience, can accurately identify and diagnose the Crohn's disease and the gastrointestinal Behcet's disease, is suitable for clinically identifying the Crohn's disease and the gastrointestinal Behcet's disease, helps a clinician to preliminarily distinguish the Crohn's disease and the gastrointestinal Behcet's disease under the condition that only common laboratory indexes are used, and improves the detection accuracy of the Crohn's disease and the gastrointestinal Behcet's disease. The situation that the optimal treatment opportunity of a patient is delayed due to misdiagnosis can be avoided, optimal disease management is achieved, and the good clinical application value is achieved.
Absstract of: CN121142055A
The invention discloses application of protecting histidine as a biomarker in predicting the treatment effect of patients with inflammatory bowel diseases. By detecting the histidine level in the plasma of the patient with the inflammatory bowel disease, the responsiveness of the patient with the inflammatory bowel disease to the thiopurine medicine can be effectively predicted in the initial treatment stage, then the treatment effect of the patient is predicted, formulation of an individualized treatment scheme is achieved, and the treatment accuracy and effectiveness are remarkably improved; the invention further provides application of histidine in preparation of a product for reducing the inflammation level, the TNF-alpha level can be effectively reduced by additionally adding histidine in the treatment process, and then the anti-inflammation effect is achieved.
Absstract of: CN121108103A
In meat freshness evaluation, biogenic amines, especially cadaverine, are key indexes. The novel fluorescent probe ZY1 provided by the invention reacts with cadaverine to realize efficient and rapid detection of meat freshness. The probe has excellent selectivity and ultralow detection limit (LDD = 13.8 nM), and is accompanied by remarkable fluorescence color conversion (light red to bright green). Based on the characteristic, the ZY1 is innovatively integrated with RGB analysis software of a smart phone, and a reliable linear relation between a G/B value and food preservation time is established by shooting a meat extracting solution loaded with the ZY1, so that real-time and portable detection of the food freshness is realized. In view of specific up-regulation of cadaverine biosynthesis in ulcerative colitis (UC), the research further proves the application potential of ZY1 in UC noninvasive auxiliary diagnosis. In addition, ZY1 also shows expanded application in the technical fields of preparation of novel fluorescent materials and information transmission.
Absstract of: WO2025253423A1
A new microbial consortium for use in a rapid screening method for irritable bowel syndrome (IBS) and possibly as a target for the therapeutic treatment of an IBS condition in a subject.
Absstract of: WO2025253316A1
The present disclosure relates to the use of angiotensin-converting enzyme and/or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.
Absstract of: US2025376514A1
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL-17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
Absstract of: AU2024260758A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Absstract of: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: CN121087164A
The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.
Absstract of: CN121081471A
The invention relates to the field of biological pharmacy, and provides application of CHI3L1 in preparation of medicines for diagnosing and treating ulcerative colitis. The invention discloses an application of a CHI3L1 inhibitor (K284-6111) in development of a medicine for preventing and treating UC, and an application of a reagent for detecting the expression level of CHI3L1 in development of a UC diagnostic tool. The effect of K284-6111 in UC treatment is explored through a DSS-induced mouse model, and a new UC treatment method is provided. The invention provides a high-specificity biomarker for UC diagnosis and application of the high-specificity biomarker in UC prevention and treatment.
Absstract of: CN121065326A
The invention discloses an intestinal flora marker related to metabolic heterogeneity of azathiopurine (AZA) and application of the intestinal flora marker, and belongs to the technical field of personalized drug treatment of inflammatory bowel diseases (IBD). In particular, the invention finds that a specific intestinal flora marker is significantly related to the level of an AZA active metabolite 6-thiopurine nucleotide (6-TGN). For example, the prevotella abundance can be used for distinguishing IBD patients with different 6-TGN exposure levels, has an indication effect on the in-vivo 6-TGN concentration, and has an important application value in thiazopurine therapeutic drug monitoring (TDM). In addition, clostridium species Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are significantly enriched in a 6-TGN high-exposure patient group, and the microbiome of the clostridium sp.OF09-36 and Clostridium sp.AF32-12BH encodes enzyme genes participating in purine metabolism, such as GMPS, HPRT, IMPDH and the like, which indicate that the Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are potential intestinal flora targets for regulating and controlling AZA metabolism. The intestinal flora marker provided by the invention provides a new biomarker and an intervention target for optimization and adjustment of AZA therapeutic dose and individualized precise treatment of IBD.
Absstract of: US2025368724A1
0000 The present invention provides a therapeutic agent for sepsis and/or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and/or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.
Absstract of: AU2024273758A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Absstract of: WO2025250163A1
Apparatus and associated methods relate to evaluating impurity content in battery materials. In an illustrative example, a battery material impurity assessment system (BMIAS) may include a slurry mixing system and an impurity extraction system (IBS). The slurry mixing system, for example, may include a motor configured to rotate a vertical axis of a slurry container. For example, the motor may pause a movement of the slurry container when the vertical axis is rotated at a predetermined angle. For example, the IBS may include a translatable magnetic mass (TMM) enclosed within a sheath. For example, by operating a position of the TMM, the IBS may release non-target impurity and retain target substances. In some implementations, the target substance may be ionized by an acid treatment solution rapidly without direct heating. In some implementations, the target substances may be dispersed on a conductive filter to be directly used in subsequent analysis. Various embodiments may advantageously rapid high precision and rapid impurity testing for battery manufacturing.
Absstract of: US2025366831A1
A system and a method for diagnosis and monitoring of inflammatory bowel diseases (IBD) in a subject are provided. The system includes a memory and a control system. The memory stores machine-readable instructions. The control system includes one or more processors configured to execute the machine-readable instructions. Ultrasound image data associated with the gastrointestinal tract of the subject is received. The received ultrasound image data is processed to output a set of ultrasound image features. The output set of ultrasound image features is received, as an input to an automated algorithm. A set of radiomic features is extracted from the input set of ultrasound image features, using the automated algorithm. The ultrasound image data is classified as normal or abnormal based on the extracted set of radiomic features, the classifying being an output of the automated algorithm.
Absstract of: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Absstract of: CN121049497A
一种均相检测体系，包括能量供体和能量受体，所述能量供体和所述能量受体的信号源至少有两种，所述信号源的可区分度包括激发波长、发射波长和/或发光寿命。由于信号源至少有两种，使得至少有两种不同的待测样本可以被同时测量，当信号源满足合适的条件，不同种类的敏化剂按照不同的比例混合，则其激发波长可以覆盖全色域。因而在均相检测时，任何待检测样本在通量满足的前提下均可以一次性检测完毕，只需要光源按照既定的程序全波段闪烁激发。既可以实现相同样本的高通量检测，也可以实现不同样本的一次性检测，提高了检测效率。
Absstract of: CN121041328A
The invention belongs to the field of biological medicines, and particularly relates to application of Clostridium baumannii in preparation of a product for treating and/or preventing inflammatory bowel diseases.
Absstract of: MX2025010187A
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Absstract of: CN121015828A
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a heat-purging stagnation-removing traditional Chinese medicine compound preparation and a preparation method and application thereof. The traditional Chinese medicine compound preparation for purging heat and removing stagnation is prepared from the following raw materials in parts by weight: 10-60 parts of radix bupleuri, 10-30 parts of radix scutellariae, 10-30 parts of radix paeoniae rubra, 10-30 parts of rhizoma pinelliae preparata, 10-40 parts of fresh ginger, 10-40 parts of fructus aurantii, 10-40 parts of cortex mori radicis, 10-30 parts of peach kernels, 10-30 parts of liquorice, 1-15 parts of cassia twig, 10-30 parts of fructus forsythiae, 1-15 parts of rhizoma cimicifugae and 8-30 parts of honeysuckle. The traditional Chinese medicine compound preparation for purging heat and removing stagnation is a self-formulated formula, takes bowel purging, heat purging, blood circulation promoting and blood stasis removing as main treatment methods, improves clinical symptoms of patients suffering from systemic inflammatory reaction, reduces the incidence rate of multi-organ dysfunction, and improves the living quality and prognosis of the patients.
Absstract of: NZ762152A
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Absstract of: WO2025245006A1
Provided herein arc systems and methods for testing exhaled breath from a subject (e.g., suspected of having inflammatory bowel disease, IBD) to determine the level of at least one volatile organic compound (e.g., 1 or 5 or 8 compounds). In certain embodiments, one receives test results, such as an elevated or decreased level of a particular volatile organic compound, and this is used to determine if a subject has IBD or needs treatment with an IBD treating agent. In other embodiments, the subject is treated with an IBD treating agent, and optionally tested again to monitor treatment (e.g., tested over days, weeks, or months). In other embodiments, the subject is determined to have moderate or severe IBD, or mild or no IBD.
Absstract of: WO2025244988A1
Disclosed are methods of characterizing, diagnosing, monitoring, and/or treating an individual with Crohn's Disease (CD) comprising detecting, in a biological sample obtained from the individual, a plurality of biomarkers. The biomarkers may be used for one or more of predicting remission of CD in an individual, determining longitudinal assessment of response to a biologic therapy, predicting or determining response status of the individual to an anti-tumor necrosis factor (TNF) therapy. Further disclosed are systems and compositions for use with the disclosed methods.
Absstract of: WO2025244478A1
The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.
Absstract of: CN120983481A
The invention relates to an application of a Blautia pseudococcoides bacterium in preparation of a medicine for treating ulcerative colitis, in particular to an application of the Blautia pseudococcoides bacterium in preparation of a medicine for treating ulcerative colitis. Specifically, the invention provides an application of the Blauria pseudococcoides bacterium in preparation of a medicine for preventing and/or treating the inflammatory bowel disease, and the preservation number of the Blauria pseudococcoides bacterium is DSM26115. Furthermore, the present invention relates to a composition for diagnosing inflammatory bowel disease comprising an agent for measuring the level of enteric microorganisms, a kit comprising the composition, and a method for diagnosing inflammatory bowel disease comprising a step of measuring the level of enteric microorganisms.
Absstract of: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Absstract of: JP2025171299A
To provide: a technique that can predict the prognosis of inflammatory bowel disease, can contribute to verifying treatment effects at that point in time, imposes less physical burden, and has high accuracy (low likelihood of missing individuals at risk of worsening disease); and a technique that can contribute to diagnosing inflammatory bowel disease, imposes less physical burden, and enables inexpensive and rapid testing of the likelihood of contracting inflammatory bowel disease.SOLUTION: A method for predicting the prognosis of inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject. A method for testing inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject.SELECTED DRAWING: Figure 6
Absstract of: WO2025240975A1
Pulmonary arterial hypertension (PAH) exhibits an obliterative vasculopathy where complex, integrated pathobiological signaling pathways drive vascular remodeling. In PAH, the arteriopathy includes numerous endophenotypes that occur to differing extents across patients. Variability in the proteomic and genetic profile is observed, causing phenotypic heterogeneity and inconsistent clinical responses to drug therapies. We have used network medicine to discover modifiable therapeutic targets in PAH by generating patient-specific protein-protein interaction (PPI) networks to unmask molecular interactions that identify and distinguish groups of individual patients with the same clinical phenotype. This allows personalized clinical phenotyping in PAH in those patient groups. The findings here also clarify the relationship between PAH genetic risk and pathobiology on an individual patient level, and inform treatment rationales and personalized drug selection using the PPI networks. Overall, findings from this project will advance precision medicine in PAH with direct relevance to the clinical management of patients.
Absstract of: AU2024265914A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Absstract of: CN118581208A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
Absstract of: TW202544255A
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Absstract of: CN120945033A
The invention discloses a tissue resident bacterium marker for identifying normal colorectal tissue, polyp and intestinal cancer and application of the tissue resident bacterium marker. According to the present invention, the tissue resident bacterium markers comprise Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides, Collinsella and Parvimonas, and can be used to reflect the biological specificity of patients, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers; according to the present invention, with the combination model of the six bacteria such as Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides and Collinsella, the normal tissue and polyp of the colorectum can be accurately identified, and the accuracy is improved by 12.5% compared with the accuracy of the existing non-invasive screening method; the polyp and the intestinal cancer can be more accurately identified by a combined model of four bacteria, namely, Pseudomonas, Pigmentiphaga, F
Absstract of: CN120958143A
The present invention provides compositions and methods for diagnosing disease, assessing disease activity, monitoring mucosal healing, and predicting therapeutic response using fecal-derived eukaryotic nucleic acid biomarkers. The biomarkers can be used by practitioners for better diagnosis, management and treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Absstract of: WO2025233942A1
The present invention provides a system for diagnosing, treating, or both, a condition or a disease associated therewith, in a subject in need thereof, the system including a synthetic microbiome including recombinant cells. Further provided are a composition including the system, a kit, a method of using same.
Absstract of: WO2025232867A1
A method for detecting anxiety and/or depression metabolic and microbiome markers in a patient with irritable bowel syndrome (IBS) is provided. The method begins with obtaining a serum sample and a fecal sample from the patient. Both samples are processed to extract a gut metagenome, including a bacteriome, a mycobiome, and a virome of the patient, and metabolic features. A classifier is utilized to detect whether a marker set of microbial species and metabolites for depression and anxiety is present in the gut metagenome and the metabolic features.
Absstract of: CN120927854A
The invention discloses an exhaled gas VOC (volatile organic compound) marker for detecting inflammatory bowel diseases and a detection system thereof. The marker is a combination of one or more of the following components: methyl propyl sulfide, propionaldehyde, cyclohexanone, allyl methyl sulfide, octanal, 2-pentanone, phenol, butyric acid, propionic acid and 3-methylheptane. The detection system comprises an exhaled air sampling module, a sample preprocessing module, a detection analysis module and a data analysis module. The marker provided by the invention has the advantages of high specificity and good stability, can realize accurate noninvasive diagnosis of IBD, and can assist in realizing early screening and dynamic monitoring in a clinical environment.
Absstract of: CN120904133A
The invention provides an HClO activated diagnosis and treatment fluorescent prodrug as well as a synthesis method and application thereof, and the fluorescent prodrug has the Chinese name of 5-(3, 7-bis (dimethylamino)-10H-phenothiazine-10-formamido)-2-hydroxybenzoic acid. The invention also provides a synthesis method of the fluorescent prodrug. The fluorescent prodrug constructed by the invention can be specifically and rapidly activated by HClO (lt, 5min), releases near-infrared fluorophore methylene blue and a first-line drug 5-aminosalicylic acid for inflammatory bowel diseases, and has excellent specificity and sensitivity. In addition, response products are analyzed through high-resolution mass spectrometry, effective release of methylene blue and 5-aminosalicylic acid is proved, and feasibility of the compound serving as a prodrug for diagnosis and treatment of the inflammatory bowel disease is shown. According to the diagnosis and treatment fluorescent prodrug, non-invasive fluorescence imaging and treatment components are combined, and reasonable design and application of diagnosis and treatment integrated molecules are achieved.
Absstract of: CN120905354A
The invention relates to the field of genetic typing, and discloses a plectropomus leopardus generic genome typing method based on low-cost DNA extraction, which comprises the following steps: carrying out DNA sampling extraction on plectropomus leopardus to construct a re-sequencing library, processing DNA data of all high-depth groups in the re-sequencing library by using Shape software, constructing a haplotype database, and carrying out genotyping on the haplotype database. And performing genotype filling on the low-depth sequencing individuals to obtain haplotypes and genotypes of the low-depth sequencing individuals, and establishing a generic genome IBD cluster typing technology. And finally, generating an individual-level report of the target plectropomus leopardus. According to the invention, a lossless, simple and low-cost DNA extraction technology for the plectropomus leopardus can be established, large-scale sample application is realized, and the purpose of generic genome typing of the plectropomus leopardus is realized.
Absstract of: WO2025229605A1
New and useful computer-implemented methods; methods of identifying markers associated with enteropathies; methods of determining the level of severity of an enteropathy; and determining a treatment for an enteropathy; are disclosed. In addition, the present disclosure provides methods of identifying a biological response to one or more treatments for an enteropathy, and whether a given treatment to an enteropathy results in a therapeutic or adverse effect, as determined in a spatiotemporal manner throughout the entirety of the small bowel, or a region of interest therein.
Absstract of: WO2025230979A1
Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting TNFAIP3 (e.g., hTNFAIP3); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the RNA agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing TNFAIP3 expression (e.g., mRNA expression), methods of treating TNFAIP3 associated diseases, and methods of treating proinflammatory (e.g., autoimmune) diseases (e.g., inflammatory bowel disease); and cancer.
Absstract of: US2025340627A1
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
Absstract of: WO2024189211A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Absstract of: CN120958131A
Provided herein are methods for treating or preventing pouch inflammation comprising administering a SMAD7 antisense oligonucleotide or a pharmaceutical formulation comprising the SMAD7 antisense oligonucleotide.
Absstract of: JP2025098004A
To provide methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC).SOLUTION: The present invention provides a method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1)/Macrophage Stimulating 1 Receptor (MST1R) pathway.SELECTED DRAWING: None
Absstract of: CN120882881A
The present invention relates generally to methods and diagnostic applications for treating ulcerative colitis. More specifically, the methods and diagnostic applications of the invention relate to the expression profiles of certain gene transcripts in ulcerative colitis patients and the use of the expression profiles of these gene transcripts for therapy and/or diagnosis in subpopulations of patients suffering from ulcerative colitis.
Absstract of: CN120877279A
The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).
Absstract of: CN120859955A
The invention discloses a xylosidase response type chemiluminescent microsphere, a preparation method thereof and application of the xylosidase response type chemiluminescent microsphere in colitis in-situ diagnosis and treatment. The preparation method comprises the following steps: firstly, synthesizing a novel chemiluminescent probe specifically responsive to xylosidase and hyperbranched polyxylose targeting intestinal flora, then coupling the chemiluminescent probe and the hyperbranched polyxylose to prepare a functional diagnosis and treatment agent, and preparing the xylosidase responsive chemiluminescent microspheres through an electrospray technology. The xylose enzyme response type chemiluminescent microspheres provided by the invention can be delivered by oral administration, release a functional diagnosis and treatment agent in a pH environment of colon, monitor the activity of probiotics in the intestinal tract in vivo in situ, synchronously realize targeted regulation and control of the activity of the probiotics in the colon, and promote up-regulation of tight junction protein in the intestinal tract and tissue repair and regeneration.
Absstract of: US2025332230A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Absstract of: WO2025226885A1
The present invention relates to a biomarker associated with intestinal inflammation, and more particularly, to methods for diagnosing or identifying a risk of developing intestinal inflammation using mitochondrial DNA and methods of treating disorders associated with intestinal inflammation.
Absstract of: WO2025224462A1
The invention relates to DNA methylation and gene expression signatures for assessing the severity of IBD in a patient, monitoring the progression of IBD in a patient, and/or determining the efficacy of a therapeutic agent for treating IBD in a patient. The DNA methylation and gene expression signatures of the invention can also be used for the differential diagnosis of Crohn's Disease or Ulcerative Colitis in a patient having or suspected of having IBD. The invention further relates to intestinal epithelial organoids (IEOs) for predicting the efficacy of therapeutic agents and for screening agents for use in treating IBD. The invention further relates to therapeutic agents for use in treating IBD.
Absstract of: US2025334593A1
In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Absstract of: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Absstract of: JP2025161855A
To provide compositions and methods useful in treating inflammation of the gut, such as inflammation associated with inflammatory bowel disease, by modulating γδ T cells (e.g., Vγ4+ cells).SOLUTION: Particular embodiments include: Vγ4+ cells expressing heterologous protein; polynucleotides containing genes contributing to functional expression of BTNL3, BTNL8, and HNF4A; methods of treating a subject using Vγ4+ cells or gene therapy; and methods of identifying a subject having mutations associated with inflammation of a gut. Compositions and methods of the invention can be used in treatment of inflammation and cancer of the gut.SELECTED DRAWING: None
Absstract of: CN120831477A
The invention discloses a novel target of PPP2R1A as an anti-inflammatory therapeutic drug and application of the novel target, it is found for the first time that knock-down of PPP2R1A can significantly inhibit expression of an anti-inflammatory active compound PB in NF-kB, TNF-alpha and IL-1beta inflammatory factors in human colon tumor cells, and at present, the relationship between PPP2R1A protein and inflammation has not been researched. The invention provides a novel drug target for treatment of inflammatory diseases in the field, provides a practical and effective screening method for discovery of inflammation treatment leading drugs, provides a scientific basis for clinical treatment of ulcerative colitis, and has a good application prospect in the aspect of anti-inflammation.
Absstract of: WO2025218823A2
Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.
Absstract of: CN120818052A
The present invention relates to novel antibodies and antibody fragments that specifically bind to IL-15 and to compositions containing said antibodies or antibody fragments. Furthermore, the present invention relates to nucleic acids encoding said antibodies or antibody fragments thereof and host cells comprising the same, as well as related uses. In addition, the invention relates to therapeutic and diagnostic uses of these antibodies and antibody fragments.
Absstract of: CN120818054A
The invention belongs to the field of immunology, and relates to an anti-CEACAM1 single-domain antibody and application thereof. The single-domain antibody is composed of heavy chains, and the heavy chains comprise a heavy chain CDR1 as shown in SEQ ID NO: 28 or SEQ ID NO: 29, a heavy chain CDR2 as shown in any one of SEQ ID NO: 30 to SEQ ID NO: 32, and a heavy chain CDR3 as shown in any one of SEQ ID NO: 33 to SEQ ID NO: 35. Compared with the prior art, the invention has the beneficial effects that the single-domain antibody specifically aiming at CEACAM1 is screened by using a biological genetic engineering technology, and the affinity of the antibody is better.
Absstract of: CN120818056A
The invention discloses an antibody or an antigen binding fragment capable of specifically recognizing and/or binding an anti-interleukin 6 receptor. Belongs to the field of antibody engineering. The antibody or the antigen binding fragment provided by the invention has higher biological activity, FcRn affinity and stronger antibody stability, and has a good clinical application prospect.
Absstract of: CN120818614A
The invention discloses a microbial marker for treating Crohn's disease based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dialister insight, Roseburia intestinae, Parabacteroides verdeae, Bacteroides caccae, Blauria obeum, Bacteroides intestinae, Paraprevotella, and a combination of the Bacteroides cactinae, and further comprises the following components in parts by weight: 1, 1, 2, 3, 4, 5, 6, 7, 7, 8, 8, 8, 9, 10, 12, 13, 13, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17 According to the invention, through metagenome sequencing and a machine learning algorithm, the key microbial marker which is significantly related to the symptom improvement of the Crohn's disease in the coprophilous fungus transplantation treatment process is screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of the Crohn's disease.
Nº publicación: CN120820665A 21/10/2025
Applicant:
ZHEJIANG UNIV
\u6D59\u6C5F\u5927\u5B66
Absstract of: CN120820665A
The invention discloses a biomarker for identifying superior mesenteric artery dissection related intestinal dysfunction. The biomarker is lysophospholipid. By means of the biomarker, a patient with intestinal dysfunction caused by SISMAD can be recognized in an early stage, operation intervention (mainly stent implantation) can be conducted in time, and malignant consequences such as intestinal necrosis, large-area intestinal resection, short bowel syndrome and infection death are avoided.
BOPI
Electronic site
